Results 171 to 180 of about 31,548,076 (283)

Stress Hyperglycemia Drives CD4+ T Cell PANoptosis and Postoperative Organ Injury via Monocyte‐Derived Succinate

Advanced Science, EarlyView.
High glucose is linked to reduced succinate dehydrogenase activity in CD14+ monocytes, accompanied by succinate accumulation and extracellular release. Extracellular succinate exacerbates mitochondrial ROS production and mtDNA release in CD4+ T cells. Cytosolic mtDNA then activates Z‐DNA binding protein 1 (ZBP1) and engages ZBP1‐associated inflammatory
Shuai Zhao, Xuemei Miao, Wei Luo, Tao Liu, Yang Wang, Jiaying Li, Di Fu, Weiyun Shen, Yan Luo, Kang Chen, Ruping Dai, Hui Li   +11 more
wiley   +1 more source

Associations of circulating insulin-like growth factor-1 and insulin-like growth factor binding protein-3 with the expression of stem cell markers in benign breast tissue. [PDF]

Breast Cancer Res
Yaghjyan L, Heng YJ, Sardella BR, Murthy D, Mahoney MB, Rosner B, Polyak K, Ratcliff M, Tamimi RM.   +8 more
europepmc   +1 more source

circZNF148 Drives Glucose Metabolism Reprogramming to Enhance Metastasis and Immune Evasion via HK1 Stabilization in Triple‐Negative Breast Cancer

Advanced Science, EarlyView.
CircZNF148 stabilizes HK1 through deubiquitinase recruitment, thereby enhancing glycolysis and lactate production. Elevated lactate promotes PD‑L1 lactylation and membrane accumulation while suppressing CD8+ T‐cell cytotoxicity, collectively facilitating immune evasion and malignant progression in TNBC.
Yuhan Jin, Wenjing Zhao, Lei Wang, Jianing Wang, Keying Zhao, Dan Luo, Yifei Wang, Yuxia Yang, Jingze Yang, Yaming Li, Tong Chen, Dianwen Han, Zekun Wang, Xiaoyan Li, Bing Chen, Lijuan Wang, Yiran Liang, Qifeng Yang   +17 more
wiley   +1 more source

Insulin-like growth factor-binding protein-3 is induced by tamoxifen and fulvestrant and modulates fulvestrant response in breast cancer cells. [PDF]

Front Oncol
Flynn KL, Zheng Y, Sowers JY, Masangya NJT, Houston KD.   +4 more
europepmc   +1 more source

Insulin-Like Growth Factor Binding Protein-3 (IGFBP-3): Unraveling the Role in Mediating IGF-Independent Effects Within the Cell. [PDF]

Front Cell Dev Biol, 2020
Varma Shrivastav S, Bhardwaj A, Pathak KA, Shrivastav A.   +3 more
europepmc   +1 more source

Insulin-Like Growth Factor Binding Protein-3: Insulin-Like Growth Factor Independence Comes of Age [PDF]

Endocrinology, 2006
openaire   +1 more source

Ferroptosis Suppression by the M6A Reader IGF2BP1 Underlies Gemcitabine Resistance in Pancreatic Ductal Adenocarcinoma

Advanced Science, EarlyView.
IGF2BP1 promotes gemcitabine resistance in pancreatic cancer by stabilizing m6A‐modified FTH1 transcripts and protecting them in stress granules, thereby suppressing ferroptosis. Pharmacological inhibition of IGF2BP1 disrupts this protective pathway, restores ferroptotic sensitivity, and enhances gemcitabine efficacy in resistant tumors.
Ying‐Qin Zhu, Yue Huang, Jing‐Yuan Ye, Si‐Yuan Lu, Zhi‐De Liu, Ming‐Jian Ma, De‐Liang Fang, Zi‐Yi Zhao, Jin‐Zhao Xie, Jiao Chen, Xiao‐Yu Yin   +10 more
wiley   +1 more source

Paracrine senescence of human endometrial mesenchymal stem cells: a role for the insulin-like growth factor binding protein 3. [PDF]

Aging (Albany NY), 2020
Vassilieva I, Kosheverova V, Vitte M, Kamentseva R, Shatrova A, Tsupkina N, Skvortsova E, Borodkina A, Tolkunova E, Nikolsky N, Burova E.   +10 more
europepmc   +1 more source

Engineered Brain‐Targeted Exosomes Delivering FGF1 for Sustained Glycemic Regulation and Multitarget Neurovascular Protection in Diabetic Stroke

Advanced Science, EarlyView.
ABSTRACT Diabetic stroke is characterized by a hyperglycemic and pro‐inflammatory microenvironment that exacerbates neurovascular dysfunction. However, the blood–brain barrier (BBB) remains a formidable obstacle, restricting the delivery of most therapeutic molecules.
Bixin Shen, Chengxiang Zhang, Junhui Wang, Xichong Zhong, Shihao Chen, Xue Wang, Xiaokun Li, Li Lin   +7 more
wiley   +1 more source

Clinicopathological correlation of insulin-like growth factor binding protein 3 and their death receptor in patients with gastric cancer. [PDF]

Res Pharm Sci
Ansari A, Gheysarzadeh A, Sharifi A, Mofid MR.   +3 more
europepmc   +1 more source